D Scott LaMontagne1, Emmanuel Mugisha2, Yuanji Pan3, Edward Kumakech2, Aloysius Ssemaganda4, Troy J Kemp5, Jane Cover6, Ligia A Pinto5, Mahboobeh Safaeian7. 1. PATH, Seattle, USA. Electronic address: slamontagne@path.org. 2. PATH, Kampala, Uganda. 3. National Cancer Institute, Bethesda, MD, USA. 4. Uganda Virus Research Institute, UVRI-IAVI HIV Vaccine Program, Entebbe, Uganda. 5. HPV Immunology Laboratory, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA. 6. PATH, Seattle, USA; PATH, Kampala, Uganda. 7. National Cancer Institute, Bethesda, MD, USA. Electronic address: safaeianm@mail.nih.gov.
Abstract
BACKGROUND: Investigations of vaccine efficacy and immunogenicity for adult females receiving fewer than three doses of human papillomavirus (HPV) vaccine have suggested protection against infection and precancerous lesions. We investigated the immunogenicity of bivalent HPV vaccines among adolescent girls from Uganda who received one, two, or three vaccine doses. METHODS: Young girls vaccinated through a government program in Uganda were invited to participate. HPV16- and HPV18-specific antibodies were measured at ≥24 months after the last vaccine dose using an enzyme linked immunoassay in girls who received one (n=36), two (n=145), or three (n=195) doses. RESULTS: Nearly all subjects (99%) were HPV16 and HPV18 seropositive at the time of blood-draw. Geometric mean antibody levels (GMTs) were: HPV16₁-dose=230 EU/mL, HPV16₂-dose=808 EU/mL, and HPV16₃-dose=1607 EU/mL; HPV18₁-dose=87 EU/mL, HPV18₂-dose=270 EU/mL, and HPV18₃-dose=296 EU/mL. The GMT ratio for 2:3 doses was 0.50 (HPV16) and 0.68 (HPV18) and did not meet the non-inferiority criteria (i.e., lower bound of 97.5% confidence interval of the GMT ratio greater than 0.50). The GMT ratio for 1:3 doses for HPV16 and HPV18 was inferior, but absolute GMTs for one dose were higher than adult women who received one dose (HPV16=124 EU/mL, HPV18=69 EU/mL) where efficacy has been demonstrated. CONCLUSIONS: Even though immunogenicity with less than three doses did not meet a priori non-inferiority thresholds, antibody levels measured ≥24 months after last dose were similar to those of adult women who have been followed for more than eight years for efficacy.
BACKGROUND: Investigations of vaccine efficacy and immunogenicity for adult females receiving fewer than three doses of human papillomavirus (HPV) vaccine have suggested protection against infection and precancerous lesions. We investigated the immunogenicity of bivalent HPV vaccines among adolescent girls from Uganda who received one, two, or three vaccine doses. METHODS: Young girls vaccinated through a government program in Uganda were invited to participate. HPV16- and HPV18-specific antibodies were measured at ≥24 months after the last vaccine dose using an enzyme linked immunoassay in girls who received one (n=36), two (n=145), or three (n=195) doses. RESULTS: Nearly all subjects (99%) were HPV16 and HPV18 seropositive at the time of blood-draw. Geometric mean antibody levels (GMTs) were: HPV16₁-dose=230 EU/mL, HPV16₂-dose=808 EU/mL, and HPV16₃-dose=1607 EU/mL; HPV18₁-dose=87 EU/mL, HPV18₂-dose=270 EU/mL, and HPV18₃-dose=296 EU/mL. The GMT ratio for 2:3 doses was 0.50 (HPV16) and 0.68 (HPV18) and did not meet the non-inferiority criteria (i.e., lower bound of 97.5% confidence interval of the GMT ratio greater than 0.50). The GMT ratio for 1:3 doses for HPV16 and HPV18 was inferior, but absolute GMTs for one dose were higher than adult women who received one dose (HPV16=124 EU/mL, HPV18=69 EU/mL) where efficacy has been demonstrated. CONCLUSIONS: Even though immunogenicity with less than three doses did not meet a priori non-inferiority thresholds, antibody levels measured ≥24 months after last dose were similar to those of adult women who have been followed for more than eight years for efficacy.
Authors: Molly A Feder; Shalini L Kulasingam; Nancy B Kiviat; Constance Mao; Erik J Nelson; Rachel L Winer; Hilary K Whitham; John Lin; Stephen E Hawes Journal: J Womens Health (Larchmt) Date: 2019-07-02 Impact factor: 2.681
Authors: Aimée R Kreimer; Mark E Sherman; Vikrant V Sahasrabuddhe; Mahboobeh Safaeian Journal: J Natl Cancer Inst Date: 2015-02-02 Impact factor: 13.506
Authors: Aimée R Kreimer; Frank Struyf; Maria Rowena Del Rosario-Raymundo; Allan Hildesheim; S Rachel Skinner; Sholom Wacholder; Suzanne M Garland; Rolando Herrero; Marie-Pierre David; Cosette M Wheeler; Paula González; Silvia Jiménez; Douglas R Lowy; Ligia A Pinto; Caroline Porras; Ana Cecilia Rodriguez; Mahboobeh Safaeian; Mark Schiffman; John T Schiller; John Schussler; Mark E Sherman; F Xavier Bosch; Xavier Castellsague; Archana Chatterjee; Song-Nan Chow; Dominique Descamps; Francisco Diaz-Mitoma; Gary Dubin; Maria Julieta Germar; Diane M Harper; David J M Lewis; Genara Limson; Paulo Naud; Klaus Peters; Willy A J Poppe; Brian Ramjattan; Barbara Romanowski; Jorge Salmeron; Tino F Schwarz; Julio C Teixeira; Wiebren A A Tjalma Journal: Lancet Oncol Date: 2015-06-09 Impact factor: 41.316
Authors: Tsetsegsaihan Batmunkh; Marguerite T Dalmau; Margad-Erdene Munkhsaikhan; Tungalagtuya Khorolsuren; Narantuya Namjil; Unursaikhan Surenjav; Zheng Quan Toh; Paul V Licciardi; Fiona M Russell; Suzanne M Garland; Kim Mulholland; Claire von Mollendorf Journal: Vaccine Date: 2020-05-07 Impact factor: 3.641